Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crizotinib inhibits activation of MET pathway caused by MET extracellular SEMA domain duplication.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2020

Lin Jiatong, Lyu Yingcheng, Li Lin, Wu Duoguang, Chen Jiewen, Lin Tengjiao, Huang Zhan, Hu Jinwei, Wang Wenjing, Lin Huayue, Wang Minghui

Abstract excerpt

OBJECTIVE: Aberrant MET activation, which promotes cell proliferation and tumor metastasis, occurs in many types of cancer and results from multiple mechanisms. A novel MET duplication mutation was found in a non-small cell lung cancer (NSCLC) patient. The clinical response to crizotinib was investigated and the functional relevance was characterized in cellular models. MATERIALS AND METHODS: Next-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Crizotinib

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 32673828
DOI: 10.1016/j.lungcan.2020.07.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crizotinib inhibits activation of MET pathway caused by MET extracellular SEMA domain duplication.PMID 32673828Read ↗

Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma PatientsSemantic proximity Read ↗

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.Semantic proximity Read ↗

Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinibSemantic proximity Read ↗

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.Semantic proximity Read ↗

Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.Semantic proximity Read ↗

Copy number gain of MET gene with low level in a metastatic lung adenocarcinoma patient represents response to salvage treatment with savolitinib and osimertinib: a case reportSemantic proximity Read ↗

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.Semantic proximity Read ↗

Multikinase Inhibitor Crizotinib Is Active in MET Exon 14-Altered Lung Cancer.Semantic proximity Read ↗

Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma.Semantic proximity Read ↗

Targeting MET Amplification: Opportunities and Obstacles in Therapeutic ApproachesSemantic proximity Read ↗

Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.